CRS-207

July 5, 2017July 5, 2017

First MPM Patient Dosed in Keytruda, CRS-207 Combo Phase 2 Trial, Aduro Says

News

Aduro Biotech has tested a novel combination treatment for malignant pleural mesothelioma (MPM) in the first patient of a Phase 2 trial (NCT03175172). MPM is the most prevalent form of ... Read more

May 24, 2017May 24, 2017

Aduro, Merck to Begin Clinical Trial Assessing CRS-207, Keytruda Combo to Treat Worsening MPM

News

Aduro Biotech has expanded its collaboration with Merck to include an additional Phase 2 trial to test a combination of Aduro’s immunotherapy, CRS-207, with Keytruda (pembrolizumab) in patients with malignant ... Read more

November 15, 2016

Aduro Presents Positive Early Data from Phase 1b Mesothelioma Trial Evaluating Combo Treatment

News

Combining the cancer vaccine CRS-207 with standard of care chemotherapy and cyclophosphamide looks like a promising first-line treatment for patients with unresectable malignant pleural mesothelioma, according to preliminary data from the second cohort of ... Read more

October 31, 2016October 31, 2016

FDA Pauses Enrollment in Trials Testing Listeria as Therapy for Mesothelioma and Other Cancers

News

The U.S. Food and Drug Administration (FDA) has placed a partial hold on all clinical trials evaluating the LADD (Listeria-based immunotherapy construct) technology platform, pausing new patient enrollment. Those already undergoing therapy will ... Read more

April 18, 2016April 18, 2016

Engineered Bacteria Seen in Phase 1 Trial in Malignant Pleural Mesothelioma Patients to Improve Response and Cancer Control

News

A new study, presented on April 14 at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland, holds promise for the treatment of pleural mesothelioma. Results from a Phase 1b trial showed ... Read more